Kerik NE, Alexanderson-Rosas E, Fermon-Schwaycer S, Ruíz-Ramírez OL, Alonso-López F

Idioma: Español
Referencias bibliográficas: 33
Paginas: 525-529
Archivo PDF: 43.63 Kb.

RESUMEN

El cáncer de pulmón es una de las principales causas de mortalidad en el mundo. Actualmente representa 25% de la mortalidad de todas las muertes por cáncer y su incidencia se encuentra en aumento. La mayoría de los cánceres pulmonares se detectan inicialmente en radiografías de tórax pero las características de las lesiones benignas son similares a las malignas. La tomografía computada (TC) es el estudio más frecuentemente utilizado para recabar información anatómica y morfológica acerca de las lesiones, pero es limitado para distinguir entre las lesiones malignas y benignas. La tomografía por emisión de positrones (PET) con fluorodeoxiglucosa (FDG) provee imágenes con información metabólica y fisiológica que caracteriza a las lesiones que son indeterminadas en TC y se utiliza en la clínica para diferenciar alteraciones pulmonares focales malignas de las benignas, así como, estadificar metástasis mediastinales y extratorácicas e identificar su recurrencia, haciéndolo el estudio de elección para la estrategia terapéutica.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Silverman DH, Hoh CK, Seltzer MA, Schlepers C, Cuan GS, Gambhir SS, Zheng L, Czemin J, Phelps ME. Evaluating tumor biology and oncological disease with positron-emission tomography. Semin Radiat Oncol 1998 Jul 8;3:183-196.

2. Coleman E. PET in lung cancer. J Nucl Med. 1999;40:814-820.

3. Stelnert H, KacI G. Tumors of the chest. En: Clinical positron emission tomography. Von Schultess GK. Lippincott Williams Wilkins Philadelphia, 2000,PP177-185.

4. Mack MJ, Hazelrigg SR, Landreneau RJ, Acuft TE. Thoracoscopy for the diagnosis of the indeterminate solitary pulmonary nodule. Ann Thorac Surg. 1993;56:825-832.

5. Ettinger DS, Kris MG, Livingston RB, Glnsberg RS, Sugarbaker DJ, Cox JD. Non-small call lung cancer practica guidelines. Oncology 1996;supp.

6. Ginsberg RS, Vokes E, Raben A. Non-small ceIl cancer of the lung. En: Cancer principies and practica of oncology. De Vita VT. Hellman S. Rosemberg SA (Eds.) Lippincot-Raven. Philadelphia, 1997, Pp 858-911.

7. Sorenson JA, Phelps ME. Nuclear medicine tomography: Systems and devicas. En: Physics in nuclear medicine. 2nd Ed. Phiiadelphia. W.B. Saunders Co., 1987, p. 434-435.

8. Thrall JH, Zlessman HA. Nuclear medicine. Mosby-Year book. USA. 1995.

9. Marti-Climent J, Penvecas I, Calvo R, Gimenez M, Gamez C, Richter J. Use of cyclotron in the production of positron emitting radionuclides. Rev Esp Med Nucl 1999;4:261-367.

10. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration en FDG uptake in cancer: a PET study. J Nud Med. 1993;34:1-6.

11. Lowe VJ, Hoffman JM, DeLong DM, Patz EF, Coleman RE. Semiquantitative and visual analysis of PET-FDG images in pulmonary abnormalities. J Nucl Med 1994;35:(11)1771-1776.

12. Patz EF, Lowe VJ, Hoffman JM, Paine SS, Burrowes P, Coleman RE, Goodman PC. Focal pulmonary abnormalities: evaluation with F-18. fluorodeoxyglucose PET scanning. Radiology 1993;188:(2)487-490.

13. Wahl RL, Quint LE, Greenough RL, Meyer GR, White Rl, Orringer MB. Staging of mediastinal non-small call lung cancar with PET-FDG, CT, and fusion images: preiiminary prospective evaluation. Radiology 1994;191:(2) 371-377.

14. Erasmus JJ, McAdams HP, Patz EF, Coleman RE, Ahuja V, Goodman PC. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol 1998;170:(5)1369-373.

15. Higashi K, Ueda Y, Seki H, Yuasa K, Oguchi M, Noguchi T, Taniguchi M, Tonami H, Oklmura T, Yamamoto I. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998;39:(6)1016-1020.

16. Dwamena BA, Fendrick AM, Wahl RL. Should PET-FDG replace CT or be used Complementary to CT in the mediastinal staging of NSCLC: Clinical and economic considerations. Radiology 1998;209(P):290.

17. Webb WR, Gatsonis C, Zerhouni EA, Heelan RT, Glazer GM, Francis IR, McNeil BJ. CT and MR imaging in staging non-small cali bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 1991;178:(3)705-713.

18. McLoud TC, Bourgouin PM, Greenberg RW, Kosiuk JP, Templeton PA, Shepard JA, Moore EH, Wain JC, Mathlsen DJ, Grillo HG. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992;182:(2)319-323.

19. Beriangieri SU, Scott AM, Knight S. Mediastinal lymph node staging in nonsmall-cell lung carcinoma: comparison of 1 BF-FDG positron emission tomography with surgical pathology (abstract). EurJ Nucl Med. 1994;21:625.

20. Buchpiguel CA, Tse K, Alavi A. Use of quantitative value FDG-PET wholebody imaging in staging lung cancer: a comparison with CT (abstract). EurJ Nucl Med. 1994;21:615.

21. Grimmel S, Starck M, Henrich M. Diagnostic value of 18-FDG-PET in patients with lung caneer and lymph node metastases (abstract). Eur J Nucl Med. 1993:20:819.

22. Patz EF, Lowe VJ, Goodman PC, Hemdon J. Thoracic nodal staging with PET imaging with I8FDG in patients with bronchogenic carcinoma. Chest 1995;108:(6)1617-1621.

23. Scott WJ, Schwabe JL, Gupta NC, Dewan NA, Reeb SD, Sugimoto JT. Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose. The Members of the PET-Lung Tumor Study Group. Ann Thorac Surg 1994;58:(3)698-703.

24. Sasaki M, lchiya Y-Kuwabara Y. The usefulness of FDG-PET for the detection of mediastinal lymph node metastases in patients with non-smallcaIl lung cancer: a comparative study witx x-ray CT (abstract). Eur J Nucl Med. 1994;21:1895.

25. VaIk PE, Pounds TR, Hopkins DM, Haseman MK, Hofer GA, Grelss HB, Myers RW, Lutrin CL. Staging non-small cell lung cancar by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995;60:(6)1573-1581.

26. Sazon DA, Santiago SM, Soo Hoo GW, Khonsary A, Brown C, Mandelkem M, Blahd W, Williams AJ. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 1996;153:(1)417-421.

27. Sasaki M, lchiya Y- Kuwabara Y. The usefulness of FDG-PET for the detection of mediastinal Iymph node metastases in patients with non-smallcell lung cancer: a comparative study witx x-ray computed tomography. Eur J Nucl Med. 1996;23:741-747.

28. Bury TH, Paulus P, Benoit TH. Positron emission tomography versus computed tomography in the staging of mediastinal non-small-calI lung cancar (abstract). Eur J Nuct Med. 1995;22:946.

29. Madar I, Hoh G, Figlin RA. Cost-ffective staging of non-small-cell lung carcinoma by whole-body PET FDG imaging (abstract). J Nucl Med. 1995;36:57P.

30. Chin R- Ward R, Keyes JW, Choplin RH, Reed JC, Wallenhaupt S, Hudspeth AS, Haponik EF. Mediastinal staging of non-small-cell lung cancar with positron emission tomography. Am J Respir Cnt Care Med 1995;152:(6)2090-2096.

31. Steinert HG, Hauser M, Allemann F, Engel H, Berthold T, von Schulthess GK, Weder W. Nonsmall cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997;202:(2)441-446.

32. Weder W, Schmid RA, Bruchhaus H, Hillinger S, von Schulthess GK, Steinevt HG. Detection of extrathoracic metastases by positron emission tomography in Iung cancer. Ann Thorac Surg 1998;66:(3)886-892.

33. Lewis P; Griffln S, Marsden P, Gee T, Nunan T, Malsey M, Dussek J. Whole-body 18 F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancat 1994;344:8932-1265.